Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

Abstract: The disclosed technology includes an asbestos abatement device that includes a housing defining a housing cavity. The asbestos abatement device may include first and second inlet ports and a negative air machine outlet coupled to the housing, and a processor coupled to a circuit board positioned inside the housing cavity. The first inlet port may be configured to measure a first pressure of an asbestos containment environment and the second inlet port may be configured to measure a second pressure of an external environment. The processor may be configured to receive first and second pressure data from the first and second inlet ports, respectively, determine a pressure differential between the asbestos containment environment and the external environment based on the received first and second pressure data, determine whether the pressure differential is at or less than a threshold value, and transmit a signal to the negative air machine outlet.

Abstract: Coating compositions for application to a substrate utilizing an applicator are provided. An exemplary coating composition provided for application to a substrate utilizing an applicator with an application efficiency greater than 80% has a loss of volatiles after application through the applicator of less than about 1 weight percent based on a total weight of the coating composition. The coating composition includes a radiation-polymerizable binder; wherein the coating composition has a pre-application viscosity at a shear rate of 1000 s?1 of less than about 100 centipoise (cP); and wherein the coating composition has a post-radiation-exposure viscosity at a shear rate of 0.1 s?1 of from about 500 cP to about 150,000 cP.

Abstract: Methods and coating compositions for application to a substrate utilizing a high transfer efficiency applicator are provided. An exemplary method includes providing the coating composition to the high transfer efficiency applicator; applying the coating composition onto the substrate utilizing a high transfer efficiency applicator to form an applied layer, wherein a loss of volatiles after application through the high transfer efficiency applicator is less than about 1 weight percent based on a total weight of the coating composition; performing a partial polymerization via radiation of the applied layer; and after performing the partial polymerization of the applied layer, thermally curing and drying the applied layer. An exemplary coating composition has a pre-application viscosity, at a shear rate of 1000 s?1, of less than about 100 centipoise (cP), and a post-radiation-exposure viscosity at a shear rate of 0.1 s?1 of from about 500 cP to about 150,000 cP.

Abstract: A lift and position device and methods of use therewith designed to aid attendants in moving and propping the various selected body parts of a patient from atop a support surface, for example, a mattress. The device utilizes a base for stability, a separately powered screw jack, radial adjustment head, a cushion cradle and a single or plurality of fitted cushion(s) configured to optimally raise and lower a particular body part of a patient such as his or her arms, torso, legs, back and the like. All elements of the device are ultralight and ultra-strong, some or all of the components of the device being composed of Carbon Fiber, Aluminum, injection molded plastic, and Titanium. The device utilizes advantageous mechanics of jack technology modified to suit the specific needs of an attendant wishing to the lift, position or prop and secure a particular body part of a patient, for example, an immobile, obese or otherwise incapacitated patient.

Abstract: This disclosure relates to DNA aptamers that bind eosinophil peroxidase, including uses thereof, such as in eosinophil peroxidase detection assays. Also provided is a method for detecting the presence of eosinophil peroxidase in a sample, using the DNA aptamers that bind eosinophil peroxidase. Further provided is a kit for detecting the presence of eosinophil peroxidase in a sample, using the DNA aptamers that bind eosinophil peroxidase.

Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.

Abstract: Methods and coating compositions for application to a substrate utilizing a high transfer efficiency applicator are provided. An exemplary method includes providing the coating composition to the high transfer efficiency applicator; applying the coating composition onto the substrate utilizing a high transfer efficiency applicator to form an applied layer, wherein a loss of volatiles after application through the high transfer efficiency applicator is less than about 1 weight percent based on a total weight of the coating composition; performing a partial polymerization via radiation of the applied layer; and after performing the partial polymerization of the applied layer, thermally curing and drying the applied layer. An exemplary coating composition has a pre-application viscosity, at a shear rate of 1000 s?1, of less than about 100 centipoise (cP), and a post-radiation-exposure viscosity at a shear rate of 0.1 s?1 of from about 500 cP to about 150,000 cP.

Abstract: A lift and position device and adapter and methods of use therewith designed to aid attendants in moving and propping the various selected body parts of a patient from atop a support surface, for example, a mattress or hospital bed. The device utilizes a base for stability, a separately powered screw jack, radial adjustment head, a cushion cradle and a single or plurality of fitted cushion(s) configured to optimally raise and lower a particular body part of a patient such as his or her arms, torso, legs, back and the like. An adapter device may optionally re-orient the lift and positioning device, as appropriate, to suit the specific needs of an attendant wishing to the lift, shift, position or prop and secure a particular body part of a patient.

Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.

Abstract: According to various embodiments, there is provided a toner composition and a developer. The toner composition includes toner particles including a resin, a colorant; and a surface additive applied to a surface of the toner particles. The surface additive includes polyaniline doped strontium titanate (SrTiO3).

Abstract: A lift and position device and methods of use therewith designed to aid attendants in moving and propping the various selected body parts of a patient from atop a support surface, for example, a mattress. The device utilizes a base for stability, a separately powered screw jack, radial adjustment head, a cushion cradle and a single or plurality of fitted cushion(s) configured to optimally raise and lower a particular body part of a patient such as his or her arms, torso, legs, back and the like. All elements of the device are ultralight and ultra-strong, some or all of the components of the device being composed of Carbon Fiber, Aluminum, injection molded plastic, and Titanium. The device utilizes advantageous mechanics of jack technology modified to suit the specific needs of an attendant wishing to the lift, position or prop and secure a particular body part of a patient, for example, an immobile, obese or otherwise incapacitated patient.

Abstract: According to various embodiments, there is provided a toner composition and a developer. The toner composition includes toner particles including a resin, a colorant; and a surface additive applied to a surface of the toner particles. The surface additive includes polyaniline doped strontium titanate (SrTiO3).

Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

Abstract: According to various embodiments, there is provided a toner composition and a developer. The toner composition includes toner particles including a resin, a colorant, a charge control agent, and a surface additive applied to a surface of the toner particles. The surface additive includes strontium titanate (SrTiO3), silica (SiO2), silicon tetrachloride (SiCl4) and a charge control agent.

Abstract: The present disclosure is directed to the treatment of ischemic heart disease and clinical conditions associated with ischemic heart disease. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in cardioprotective effects against acute myocardial infarction, such as a decrease in circulating triglycerides, total cholesterol, and low-density lipoproteins, and an increase in the ratio of high-density lipoprotein to total cholesterol.

Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.

Abstract: The present disclosure is directed to the treatment of diseases or conditions characterized by the buildup of fatty tissue, or hyperphagia, such as Prader-Willi syndrome, obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain, weight loss, and/or reduction in fatty tissue, and a marked decrease in lipid synthesis and accumulation.